NCT02912572 - Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

November 14, 2016

Primary Completion Date

November 15, 2023

Study Completion Date

November 30, 2026

Conditions

Metastatic Endometrial Cancer

Interventions

DRUG

Avelumab

Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment

DRUG

Talazoparib

Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days

DRUG

Axitinib

Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days

Trial Locations (4)

60637

University of Chicago, Chicago

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston